Abstract library

84 results for "Jann".
#442 Low Diagnostic Accuracy of Tumor Markers for the Annual Screening of Pancreatic Neuroendocrine Tumors in MEN-1 Patients
Introduction: The use of tumor markers for annual screening for pancreatic neuroendocrine tumors (pNET) in Multiple Endocrine Neoplasia type 1 (MEN-1) is debatable because of low-level evidence and high costs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD PhD Gerlof Valk
#2261 Mechanisms of Main Pancreatic Duct Dilatation in Pancreatic Neuroendocrine Tumors (PanNETs): Radiopathologic Correlation
Introduction: Main pancreatic duct (MPD) dilatation, a frequent observation in cases with adenocarcinoma can also be observed in patients with PanNET.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr Jerome Cros
#1253 A Novel Hereditary Pancreatic Neuroendocrine Tumor Syndrome Associated with Biallelic Inactivation of the Glucagon Receptor
Introduction: Hereditary pancreatic neuroendocrine tumors (PanNETs) are associated with 4 known autosomal dominant syndromes including MEN1, vHL disease, NF1, and TS. Glucagon receptor (GCGR) inactivation in human (Mahvash disease) has been associated with asymptomatic hyperglucagonemia, α-cell hyperplasia, and PanNET, and may represent a new hereditary syndrome.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr. Laura Tang
Authors: Tang L, Yu R, ...
#2293 Genomic and Transcriptomic Characterization of Aggressive Well Differentiated Pancreatic Neuroendocrine Tumors (WD PanNET)
Introduction: While the genomic and transcriptomic landscape of low proliferating PanNET have been well studied, pathways driving aggressive WD PanNET are still unclear.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Jerome Cros
#1889 FNA Under Percutaneous Ultrasound or Endoscopic Ultrasound for Pre-Operative Diagnosis and Grading Determination in PanNET. Are They Reliable to Define a Tailored Therapy?
Introduction: Fine-needle aspiration cytology (FNA)under percutaneous ultrasound guided (pUS)or endoscopic ultrasound(EUS)control is a minimally invasive technique allowing diagnosis and grading determination in pancreatic neuroendocrine tumors (PanNET).Obtaining a correct cytological diagnosis is crucial for a tailored therapy
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: MD Roberta Rota
Keywords: FNA, Ki67
#1420 A New Immunohistochemistry Prognostic Score (IPS) Based on MGMT, NDRG-1 and PHLDA-3 for Recurrence and Survival in Resected Pancreatic Neuroendocrine Tumors (PanNET)
Introduction: In PanNET tumors contradictory data about the prognostic role of MGMT (O6-methylguanine DNA methyltransferase) has been published. NDRG-1 (N-myc downstream-regulated gen-1) and PHLDA-3 (Pleckstrin homology-like domain family A member 3) immunohistochemistry (IHC) expressions have been evaluated in several solid malignant tumors, but their roles in PanNET remain unknown
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Antonio Viudez
#2135 Is the Classification of Functioning-PanNET/Non-Functioning PanNET Properly? Insulinoma/Non-Insulinoma Is More Suitable to Distinguish the Clinicopathological and Prognosis Difference of Localized Insulinoma
Introduction: Pancreatic neuroendocrine tumor (PanNET) is classified into Functioning (F-PanNET) and Non-functioning (NF-PanNET) by hormone secretion. But insulinoma is slowly proliferating with unique features compared with Non-insulinoma F-PanNET (NiF-PanNET).
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Heli Gao
Authors: Gao H, Yu X, ...
#2287 Mitochondrial or Aerobic Glycolysis Oriented Metabolism May Define Pancreatic Neuroendocrine Tumors (PanNET) Resistance to mTOR-Targeting Therapies
Introduction: The mTOR inhibitor Everolimus is approved for the treatment of PanNET and no predictive biomarker is available. mTOR is a central node controlling mitochondrial and aerobic glycolytic metabolisms.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Jerome Cros
Authors: Cros J, Bucau M, Raffenne J, Soukeur M, ...
#2051 Do We Need Hormonal Therapy for Pancreatic Neuroendocrine Tumors? An Effort to Reduce the Size of PanNETs
Introduction: Pancreatic neuroendocrine tumors although rare , have been significantly increased over the past few decades. They range from indolent to highly aggressive in nature. Just like breast and endometrial carcinoma are hormonal dependant,
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...
#2278 Incidental Histological Diagnosis of Small Pancreatic Neuroendocrine Tumors: Are We Underestimating Their Incidence?
Introduction: The annual incidence of pancreatic neuroendocrine tumours (PanNET) has been estimated to be around 0.8/100,000 inhabitants.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. Fabio Giannone
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.